IAA
ESPR

Independent Advisor Alliance’s Esperion Therapeutics ESPR Stock Holding History

Independent Advisor Alliance’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,053
Closed -$27.5K – 1195
2026
Q1 		$27.5K Buy
10,053
+53
+0.5% +$168 ﹤0.01% 1577
2025
Q4 		$37K Hold
10,000
– – ﹤0.01% 983
2025
Q3 		$26.5K Hold
10,000
– – ﹤0.01% 934
2025
Q2 		$9.84K Sell
10,000
-1,356
-12% -$1.36K ﹤0.01% 887
2025
Q1 		$16.4K Sell
11,356
-2,644
-19% -$4.87K ﹤0.01% 805
2024
Q4 		$30.8K Buy
14,000
+1,000
+8% +$2.33K ﹤0.01% 1341
2024
Q3 		$21.4K Hold
13,000
– – ﹤0.01% 699
2024
Q2 		$28.9K Buy
13,000
+1,500
+13% +$3.53K ﹤0.01% 692
2024
Q1 		$30.8K Buy
11,500
+1,500
+15% +$3.65K ﹤0.01% 690
2023
Q4 		$29.9K Hold
10,000
– – ﹤0.01% 668
2023
Q3 		$9.8K Hold
10,000
– – ﹤0.01% 646
2023
Q2 		$13.9K Hold
10,000
– – ﹤0.01% 664
2023
Q1 		$15.9K Sell
10,000
-350
-3% -$1.81K ﹤0.01% 663
2022
Q4 		$64 Buy
10,350
+144
+1% +$1.03K ﹤0.01% 399
2022
Q3 		$68K Sell
10,206
-100
-1% -$687 ﹤0.01% 602
2022
Q2 		$66K Buy
10,306
+306
+3% +$1.74K ﹤0.01% 595
2022
Q1 		$46K Hold
10,000
– – ﹤0.01% 645
2021
Q4 		$50K Sell
10,000
-1,500
-13% -$12K ﹤0.01% 656
2021
Q3 		$139K Buy
+11,500
New +$167K 0.01% 601

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Independent Advisor Alliance's ESPR Position: Q2 2026 in Review

Independent Advisor Alliance sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 10,053 shares — an estimated $27.5K sold.

Independent Advisor Alliance first reported a position in ESPR in Q3 2021 and held it in 19 quarters. The position peaked at $139K in Q3 2021. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Independent Advisor Alliance reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Independent Advisor Alliance sold 10,053 Esperion Therapeutics shares in Q2 2026, an estimated $27.5K.
  • Independent Advisor Alliance first reported a position in Esperion Therapeutics in Q3 2021 and held it in 19 quarters.
  • Independent Advisor Alliance's Esperion Therapeutics position peaked at $139K in Q3 2021.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Independent Advisor Alliance's 13F filing for Q2 2026, filed 12 Aug 2026.